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*Corresponding Author. E-mail: tmilling@seton.org.96 AnnaStudy objective: We evaluated thromboembolic events after vitamin K antagonist reversal in post hoc analyses of
pooled data from 2 randomized trials comparing 4-factor prothrombin complex concentrate (4F-PCC) (Beriplex/Kcentra)
with plasma.
Methods: Unblinded investigators identiﬁed thromboembolic events, using standardized terms (such as “myocardial
infarction,” “deep vein thrombosis,” “pulmonary embolism,” and “ischemic stroke”). A blinded safety adjudication board
reviewed serious thromboembolic events, as well as those referred by an independent unblinded data and safety
monitoring board. We descriptively compared thromboembolic event and patient characteristics between treatment
groups and included detailed patient-level outcome descriptions. We did not power the trials to assess safety.
Results: We enrolled 388 patients (4F-PCC: n¼191; plasma: n¼197) in the trials. Thromboembolic events occurred in
14 of 191 patients (7.3%) in the 4F-PCC group and 14 of 197 (7.1%) in the plasma group (risk difference 0.2%; 95%
conﬁdence interval 5.5% to 6.0%). Investigators reported serious thromboembolic events in 16 patients (4F-PCC:
n¼8; plasma: n¼8); the data and safety monitoring board referred 2 additional myocardial ischemia events (plasma
group) to the safety adjudication board for review. The safety adjudication board judged serious thromboembolic events
in 10 patients (4F-PCC: n¼4; plasma: n¼6) as possibly treatment related. There were 8 vascular thromboembolic
events in the 4F-PCC group versus 4 in the plasma group, and 1 versus 6 cardiac events, respectively. Among patients
with thromboembolic events, 3 deaths occurred in each treatment group. All-cause mortality for the pooled population
was 13 per group. We observed no relationship between thromboembolic event occurrence and factor levels transiently
above the upper limit of normal; there were no notable differences in median factor or proteins C and S levels up to
24 hours postinfusion start in patients with and without thromboembolic events.
Conclusion: The incidence of thromboembolic events after vitamin K antagonist reversal with 4F-PCC or plasma was
similar and independent of coagulation factor levels; small differences in the number of thromboembolic event subtypes
were observed between treatment groups. [Ann Emerg Med. 2016;67:96-105.]
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Background
Health care providers prescribe warfarin, a vitamin K
antagonist, to more than 3.4 million patients annually in the
United States for various prothrombotic conditions.1 The
Food and Drug Administration describes warfarin as among
the top 10 drugs with the largest number of serious adverse
drug reactions submitted during the 1990s and 2000s.2
Vitamin K antagonists reduce the risk of thromboembolic
events in patients with prothrombotic conditions byls of Emergency Medicineinhibiting the synthesis of functional vitamin K–dependent
clotting factors (factor [F] II, VII, IX, and X) and proteins
C and S. Patients receiving vitamin K antagonists who
are actively bleeding or in need of an urgent surgical
procedure need rapid reversal of anticoagulation by prompt
replenishment of vitamin K–dependent clotting factors.
In the current literature and guidelines, a combination
therapy of vitamin K and either plasma or prothrombin
complex concentrate is recommended for acute reversal of
oral anticoagulation.3-8Volume 67, no. 1 : January 2016
Vo
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What is already known on this topic
Rapid reversal of warfarin anticoagulation provokes
thromboembolic events in some patients. Pooled
plasma is cheaper and more difﬁcult to use; newer 4-
factor prothrombin complex (4F-PCC) concentrates
are more expensive and easier to deliver.
What question this study addressed
Which causes more thromboembolic events and
short-term mortality when reversing warfarin: pooled
plasma or a 4F-PCC?
What this study adds to our knowledge
In examination of data from 2 independent trials
with 388 subjects, the frequency of thromboembolic
events (7.1% and 7.3%) and mortality did not differ
between pooled plasma and the newer concentrate.
How this is relevant to clinical practice
Neither pooled plasma nor 4F-PCC produces a
higher risk of new clot or death when used for rapid
reversal.The efﬁcacy of plasma for urgent vitamin K antagonist
reversal has not been established, and although it is less
expensive per unit than other reversal methods, it has
several drawbacks. Plasma may be a carrier of infective
agents, requires ABO blood typing and thawing before
use, is subject to relatively long infusion times, and can
be associated with severe adverse outcomes, including
transfusion-associated circulatory overload and transfusion-
related acute lung injury.3,9-12 In contrast, prothrombin
complex concentrates do not require cross-matching or
thawing, undergo a number of viral inactivation and
elimination steps during their manufacturing process to
minimize risk of viral transmission, do not pose a risk of
transfusion-related acute lung injury, and can be infused in
15 to 30 minutes.3
The use of prothrombin complex concentrates for
anticoagulation reversal may be associated with
thromboembolic complications; however, most of the studies
on this subject are small retrospective case studies that lack a
comparison group of other reversal agents, such as plasma.13 It
is difﬁcult to differentiate the risk of the therapy used for
anticoagulant reversal from the underlying risk of thrombosis.
Recently, 2 phase 3b randomized controlled trials comparing
the efﬁcacy and safety proﬁle of a nonactivated 4-factor
prothrombin complex concentrate (4F-PCC) (Beriplex; CSLlume 67, no. 1 : January 2016Behring,Marburg,Germany; known asKcentra in theUnited
States) versus plasma in vitamin K antagonist–treated patients
requiring urgent anticoagulation reversal (owing to acute
major bleeding14 or before emergency surgery15) were
completed. The similarity in patient demographics, treatment
regimens, and thromboembolic safety outcomes for the 2
studies may permit the pooled analysis of safety data,
providing a larger data set to compare the safety proﬁles of the
2 interventions. Therefore, we report the complete set of
thromboembolic events with patient-level narratives and
ﬁndings in addition to aggregate data.
Importance
The analysis provides a unique opportunity to evaluate
the safety proﬁle of a 4F-PCC in comparison with
plasma in terms of thromboembolic events, and deaths in
patients with those events. Safety data extend to 45 days
postinfusion, enabling the evaluation of the timing and
characterization of thromboembolic events far beyond the
immediate postinfusion period.
Goals of This Investigation
Our objective was to evaluate and compare the frequency
and characteristics of thromboembolic events that occurred
during 2 randomized controlled trials that compared a 4F-
PCC with plasma for urgent vitamin K antagonist reversal.
MATERIALS AND METHODS
Study Design and Setting
We performed a secondary post hoc analysis on safety
data collected during 2 prospective, randomized, open-
label, active-controlled, noninferiority, phase 3b trials.14,15
Patients receiving vitamin K antagonists and presenting
with acute major bleeding (NCT00708435) or in need of
urgent surgical or invasive procedures (NCT00803101)
were randomized to receive 4F-PCC (containing vitamin K–
dependent factors plus proteins C and S) or plasma.
The population evaluated in this analysis (pooled safety
population) comprised patients from both studies who
received any portion of study product.14,15 Each patient
received his or her assigned study treatment on day 1, dosed
according to baseline international normalized ratio and
body weight (Table E1, available online at http://www.
annemergmed.com)14,15; all patients were also to receive
vitamin K. Resumption of anticoagulant therapy was to be
considered after the stabilization of the acute bleeding event
or as soon after the procedure asmedically appropriate. Study
staff drew blood samples for determination of levels of
vitamin K–dependent factors and proteins C and S before
study product infusion and 0.5, 1, 3, 6, 12, and 24hours after
start of infusion.Annals of Emergency Medicine 97
Table 1. Patients with thromboembolic events: selected
demographics.
Patients With TEEs
Integrated Analysis
4F-PCC (n[14) Plasma (n[14)
Sex, No. (%)
Female 9 (64.3) 8 (57.1)
Age, y
Mean (SD) [range] 75 (13) [51–90] 72 (11) [50–92]
70, No. (%) 9 (64.3) 9 (64.3)
Type of bleeding, No. (%)*
GI/other nonvisible 4 (50.0) 5 (71.4)
Visible 1 (12.5) 0
ICH 3 (37.5) 0
Musculoskeletal 0 2 (28.6)
Type of surgery/procedure,
No. (%)†
Cranial neurosurgical 0 1 (14.3)
Cardiothoracic surgical 0 1 (14.3)
Major orthopedic surgical 2 (33.3) 3 (42.9)
Other surgical 2 (33.3) 0
Invasive procedure 2 (33.3) 2 (28.6)
Reason for oral VKA therapy,
No. (%)
Arrhythmia 9 (64.3) 10 (71.4)
Artiﬁcial heart valve or joint 0 1 (7.1)
Remote TEE 5 (35.7) 3 (21.4)
Use of anticoagulant at TEE 3 (21.4) 4 (28.6)
TEE, Thromboembolic event; GI, gastrointestinal; ICH, intracranial hemorrhage; VKA,
vitamin K antagonist.
*For patients enrolled in the bleeding study (NCT00708435) only.
†For patients enrolled in the surgery study (NCT00803101) only.
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concomitant medications at every point up to day 10 (visit
window days 7 to 11), and serious adverse events up to day
45 (visit window days 43 to 51). An independent data
and safety monitoring board reviewed unblinded data to
assess patient safety and also assessed serious adverse events
and deaths. A blinded, independent safety adjudication
board reviewed serious adverse events of interest to the data
and safety monitoring board (including thromboembolic
events) for case conﬁrmation and relatedness to study
product administration.
Any potential thromboembolic event was ﬁrst evaluated
for seriousness and relatedness by the unblinded investigator.
The unblinded independent data and safetymonitoring board
(which reviewed all adverse events) could also refer suspected
thromboembolic events to the safety adjudication board for
review. The blinded safety adjudication board evaluated any
serious thromboembolic events or data and safety monitoring
board–referred events for relatedness, meaning any
thromboembolic event had at least 1, and possibly 2,
independent evaluations for relatedness. See Appendix E1
(available online at http://www.annemergmed.com) for
further explanation of standard terms and processes.
We have previously described additional details of the
study designs, patient randomization, treatment allocation,
inclusion and exclusion criteria, and methods, as well as
efﬁcacy and top-line safety results.14,15
CSL Behring sponsored the studies, which were
performed in accordance with local ethics regulations, the
International Conference on Harmonization Good Clinical
Practice guidelines, and the Declaration of Helsinki (1996).
Investigators obtained written informed consent from all
patients before participation in any study procedure or
assessment.
Primary Data Analysis
We used data from the trial databases to generate a
report for all variables of interest for this analysis from all
patients in the pooled safety population. Variables of
interest included reason for oral vitamin K antagonist
therapy, type of thromboembolic event, relationship to
treatment, additional thromboembolic risk factors, and
time from treatment with study product to event onset. We
also evaluated the relationship between coagulation factor
and protein levels and event occurrence.
Because the trials were not powered to support any testing
of this subset of adverse event cases, we treated the testing of
data as exploratory and reported all differences with ranges
and conﬁdence intervals. We determined the conﬁdence
interval for the risk difference by the Wilson method, using
the correction for continuity.98 Annals of Emergency MedicineWe analyzed coagulation factor and protein levels at
each point with a 2-tailed Wilcoxon rank sum test for
between-group comparisons and a signed rank test for
within-group changes from baseline.
RESULTS
Characteristics of Study Subjects
The pooled safety population comprised 388 patients
(4F-PCC: n¼191; plasma: n¼197). The median
prothrombin complex concentrate dose was 25 IU/kg
(range 15.5 to 50.5 IU/kg), with a median volume of
90 mL (range 48 to 230 mL) and median infusion time of
17 minutes (range 7 to 288 minutes). The median plasma
dose was 10 mL/kg (range 3.9 to 17.7 mL/kg), median
volume 800 mL (range 353 to 1,525 mL), and median
infusion time 120 minutes (range 22 to 928 minutes). For
patients who experienced thromboembolic events, the
demographics, disease characteristics (excluding vitamin K
antagonist reversal indication), and patient disposition were
similar between the 2 studies (Table 1).14,15
Main Results
In total, 28 of 388 patients (7.2%) in this analysis
population experienced greater than or equal to 1Volume 67, no. 1 : January 2016
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14/197 [7.1%]), with a risk difference of 0.2% (95%
conﬁdence interval –5.5% to 6.0%). The breakdown by
study was 6 and 8 4F-PCC–treated patients with events in
the surgical and bleeding study, respectively, and 7 plasma-
treated patients with events in each study, for a total of
14 patients with events in each treatment group in the
combined analysis.
Three patients experienced a second thromboembolic
event, meaning that the total number of events considered
in this analysis was 31 (4F-PCC: n¼16 in 14 patients;
plasma: n¼15 in 14 patients) (Table 2). Site investigators
reported 17 thromboembolic events as serious (predeﬁned
standardized terms; 4F-PCC: n¼9; plasma: n¼8), and the
independent data and safety monitoring board referred
2 suspected thromboembolic events (myocardial ischemia,
plasma group) to the safety adjudication board for review.
The blinded safety adjudication board subsequently
conﬁrmed 16 of these 19 events as thromboembolic
(4F-PCC: n¼7; plasma: n¼9).
Eleven of 16 thromboembolic events (68.8%) in the
4F-PCC group occurred more than 7 days after infusion,
clustering in the second week (Figure). In comparison, the
majority of events in the plasma group (11/15 [73.3%])
occurred within 7 days of infusion, with 7 events (46.7%)
occurring on the day of infusion compared with 3 (18.8%)
in the 4F-PCC group (Figure).
Additional event characteristics are reported in Table 3.
There were 5 nervous system events in 5 patients in each
treatment group. Eight vascular events (in 7 patients)
occurred in the 4F-PCC group compared with 4 events in
4 patients in the plasma group. Of these vascular events, 4
deep venous thrombosis events occurred in 3 patients in
the 4F-PCC group (patient K11 and K12; event count also
includes the basilic vein clot due to peripherally inserted
central catheter in patient K6), and 1 deep venous
thrombosis (patient P7) and 1 pulmonary embolism
(patient P12) were reported in the plasma group (Tables 2
and 3). One cardiac event (myocardial infarction) occurred
in the 4F-PCC event group and 6 cardiac events (2
myocardial ischemia events [referred by the data and safety
monitoring board] and 4 myocardial infarctions/acute
myocardial infarctions) occurred in the plasma event group
(Table 3). Causality by event type is summarized in Table E2,
available online at http://www.annemergmed.com.
Patients with thromboembolic events had a variety
of underlying risk factors, the most frequent being
hypertension, atrial ﬁbrillation, coronary artery disease, and
congestive heart failure (Table E3, available online at http://
www.annemergmed.com). The majority of patients
with reported events (19/28 [67.9%]) were receivingVolume 67, no. 1 : January 2016vitamin K antagonist therapy for arrhythmias (Table 1).
The predominant type ofmajor bleeding was gastrointestinal
or other nonvisible hemorrhage (9/15 [60.0%] patients
with events in the acute bleeding study), whereas the
predominant type of surgery or procedure was major
orthopedic procedures (5/13 [38.5%] patients with events
in the surgery study) (Table 1).
Resumption of anticoagulationwas at the discretion of the
treating physician, and the majority of patients in this subset
had not resumed anticoagulation therapy at the event despite
the presence of multiple risk factors for thromboembolism
(only 3 patients in the 4F-PCC event group and 4 in the
plasma event group were receiving anticoagulant therapy at
the event) (Table 1). In addition to the nonresumption of
anticoagulant therapy, we observed that 9 of 14 patients
(64.3%) in the 4F-PCC event group and 6 of 14 (42.9%) in
the plasma event group had an event consistent with the
original indication for anticoagulation (Table E3, available
online at http://www.annemergmed.com).
Results indicate that the risk of thromboembolic events was
not proportional to dose and that dose was not associated with
the development of an event in either group. In the 4F-PCC
event group, 7 of 14 patients (50.0%) received the dose at 25
IU/kg, 3 of 14 (21.4%) received it at 35 IU/kg, and 4 of 14
(28.6%) received it at 50 IU/kg (Table E3, available online at
http://www.annemergmed.com). In the plasma event group,
5 of 14 patients (35.7%) received an actual dose of less than 10
mL/kg, 8 of 14 (57.1%) received 10 to 15mL/kg, and 1 of 14
(7.1%) received greater than 15 mL/kg (Table E3, available
online at http://www.annemergmed.com).
We summarize other characteristics for patients with and
without events, as well as for the entire pooled safety
population, in Table 4. A slightly larger proportion of
patients with events were aged 70 years or older compared
with those who did not experience an event (64.3%
versus 54.4%, respectively). A larger proportion of patients
with events had been prescribed vitamin K antagonist for
arrhythmia (67.9% versus 48.6%, respectively) or a remote
thromboembolic event (28.6% versus 17.5%, respectively)
compared with patients without an event.
The majority of patients who experienced an event
recovered without sequelae. As has been previously
reported, the 45-day all-cause mortality was 13 patients per
group for the pooled safety population (4F-PCC: 10 and 3
patients in the bleeding and surgery study, respectively;
plasma: 5 and 8 patients, respectively).14,15 Among patients
who experienced a thromboembolic event, 3 from the 4F-
PCC event group (K1, K13, and K14) and 3 from the
plasma event group (P8, P9, and P12) died during the
study (Table 2). The blinded safety adjudication board did
not adjudicate any of the deaths in the 4F-PCC eventAnnals of Emergency Medicine 99
Table 2. Details of patients with thromboembolic events (pooled safety population).
Patient Study
Onset
Day* Age Indication for VKA Standardized Term SAE
Causality†
Baseline
INR
Death
(Day)Investigator SAB
4F-PCC
K1 Bleeding 1 66 Portal vein thrombosis Thrombosis in device (ﬁstula clot/
thrombosis)
No Yes Not assessed 12.7 Yes (26)
K2 Bleeding 1 73 DVT Venous thrombosis calf vein No Yes Not assessed 5.4 No
K3 Surgery 1 64 Mitral valve replacement
and AF
Ischemic stroke Yes Yes Yes 2.7 No
K4 Surgery 6 78 DVT Vena cava ﬁlter insertion‡ No No Not assessed 3.1 No
K5 Surgery 7 62 AF Catheter-related complication (poor ﬂow in
dialysis catheter)
No No Not assessed 3.6 No
K6 Bleeding 9 54 DVT Venous thrombosis limb (basilic vein clot
at PICC line site)
No No Not assessed 9.2 No
K7 Bleeding 9 82 AF/St Jude’s valve Ischemic stroke Yes No Yes 4.4 No
K8 Bleeding 10 85 AF Ischemic stroke Yes No No 3.8 No
K9 Surgery 10 89 AF CVA No No Not assessed 2.2 No
K9 Surgery 11 As above As above Venous thrombosis limb (radial vein) No Yes Not assessed As above As above
K10 Surgery 12 51 DVT Microthrombosis of toes Yes Yes Not conﬁrmed as TEE 17 No
K11 Bleeding 13 80 AF DVT right leg Yes Yes Yes 2.2 No
K11 Bleeding 29 As above As above DVT left leg Yes No Yes As above As above
K12 Surgery 19 90 AF DVT Yes Yes Yes 3.7 No
K13 Bleeding 38 88 AF MI Yes No Not conﬁrmed as TEE 2.4 Yes (38)
K14 Bleeding 43 89 AF Ischemic stroke Yes Yes No 4.5 Yes (46)
Plasma
P1 Bleeding 1 77 AF Myocardial ischemia Yes Yes Yes 2.0 No
P1 Bleeding 4 As above As above Thrombophlebitis No No Not assessed As above No
P2 Bleeding 1 70 AF Myocardial ischemia Yes Yes Yes 3.1 No
P3 Bleeding 1 64 Aortic valve replacement Acute MI No Yes Not assessed 7.4 No
P4 Bleeding 1 75 AF CVA No No Not assessed >3.99 No
P5 Bleeding 1 79 AF Thrombosis in device (clotted NG tube) No No Not assessed 2.8 No
P6 Surgery 1 75 DVT Acute MI Yes No Yes 5.9 No
P7 Surgery 1 59 DVT DVT Yes Yes Yes 2.1 No
P8 Surgery 2 85 AF Embolic cerebral infarction Yes Yes Yes 5.6 Yes (13)
P9 Surgery 4 61 AF Acute MI Yes No Yes 2.2 Yes (8)
P10 Surgery 6 50 AF TIA No No Not assessed 4.0 No
P11 Bleeding 13 68 AF MI Yes No No 2.5 No
P12 Surgery 16 92 AF PE Yes No Not conﬁrmed as TEE 2.5 Yes (16)
P13 Bleeding 22 78 AF CVA Yes No No 3.0 No
P14 Surgery 56§ 77 DVT Acute CVA Yes No No 2.1 No
SAE, Serious adverse event; SAB, Safety adjudication board; INR, international normalized ratio; DVT, deep venous thrombosis; AF, atrial ﬁbrillation; PICC, peripheral into central circulation; CVA, cerebrovascular accident; MI,
myocardial infarction; NG, nasogastric; TIA, transient ischemic attack; PE, pulmonary embolism.
*Onset study day of thromboembolic event, day of study product infusion is day 1.
†No: event deemed unrelated to the study product in the opinion of the investigator/SAB. Yes: event deemed at least possibly related to the study product in the opinion of the investigator/SAB. SAB evaluated only events that
were SAEs and did not assess causality if the event was not conﬁrmed as a thromboembolic one.
‡The vena cava ﬁlter insertion (K4) was not considered a thromboembolic event by the lead author. The Food and Drug Administration assessed some of the adverse events and thromboembolic events differently from the study
investigators/SAB, resulting in a difference in the numbers of thromboembolic events reported in the package insert for the 4F-PCC in the United States (Kcentra)19 compared with published study results.14,15
§Acute CVA was diagnosed on day 56 but included in the thromboembolic event analysis because of uncertain timing related to the start of the event.
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Figure. Thromboembolic events over time. Three SAEs were not conﬁrmed as a thromboembolic events by the SAB; therefore, the
SAB did not assess causality for these events (plasma group: PE [day 16]; 4F-PCC group: thrombosis [day 12] and MI [day 38]);
causality indicated as assessed by investigators. AE, Adverse event; PR, possibly or probably related to the study product as
assessed by investigators (for adverse events) or SAB (for SAEs); R, related to study product as assessed by investigators (for
adverse events) or SAB (for SAEs); NR, not related to study product.
Milling et al Thromboembolic Events After Vitamin K Antagonist Reversalgroup as related to study product. Patient K1 (aged 66
years) experienced a thrombosis in device (ﬁstula clot/
thrombosis) on day 1 but died of sepsis on day 26.
Patient K13 (aged 88 years) died of unknown causes on
day 38; investigators attributed the death to a myocardial
infarction, leading the safety adjudication board to
assess it as a possible thromboembolic event. The safety
adjudication board did not categorize the case as an event
owing to its timing, lack of compatible medical history, and
unknown cause of death; hence, the board did not assess
the causality for the myocardial infarction and death.
The death of patient K14 (aged 89 years) on day 46
followed an ischemic stroke on day 43. Although the
investigator considered the ischemic stroke possibly related
to study product, the safety adjudication board did not
agree owing to the timing of the event, the lack of
anticoagulation in a patient with atrial ﬁbrillation, and
the patient’s age and comorbidities.
In the plasma group, patient P8 (aged 85 years) died
of congestive heart failure on day 13 but had experienced a
stroke (reported as embolic cerebral infarction) approximately
34 hours after plasma infusion. The investigator reported
contributing illnesses as severe tricuspid regurgitation,
pulmonary hypertension, and chronic obstructive pulmonary
disease; the safety adjudication board considered the stroke to
be possibly related to study product, citing the small intervalVolume 67, no. 1 : January 2016between the plasma administration and the event. The
death of patient P9 (aged 61 years), admitted for cardiac
catheterization and aortic valve replacement, onday8 followed
a myocardial infarction the same day and multiple coronary
occlusions and cardiac events in the days leading up to his
death. The safety adjudication board considered both the
myocardial infarction and the death to be possibly related
to study product. The death of patient P12 (aged 92 years)
on day 16 was likely due to profound anemia resulting
in congestive heart failure in an already compromised
cardiac patient, and the safety adjudication board did not
consider it related to study product.
We performed exploratory analyses to assess whether
enhanced vitamin K–dependent coagulation factor levels
were associated with thromboembolic events in this analysis
population. The distributions of these factor levels were
compared between patients with and without events in the
4F-PCC group (Figure E1, available online at http://www.
annemergmed.com). After administration of 4F-PCC, we
observed marked increases in coagulation factor levels, with
median levels returning to physiologic range or below at
0.5 hours after the start of infusion.14,15 We observed no
notable differences in median levels of coagulation factors
at 0.5 hours after start of 4F-PCC infusion in patients with
and without an event (Figure E1, available online at http://
www.annemergmed.com). Similar results were observed atAnnals of Emergency Medicine 101
Table 3. Characteristics of thromboembolic events.
Thromboembolic Events (n[Events)
Integrated Analysis
4F-PCC
(n[16)
Plasma
(n[15)
Relatedness, investigator, No. (%)
Related 1 (6.2) 0
Possible 7 (43.8) 5 (33.3)
Not related 8 (50.0) 10 (66.7)
Serious TEE, No. (%) 9 (56.3) 10 (66.7)
Relatedness (investigator) 5 (31.3) 4 (26.7)
Relatedness (SAB) 5 (31.3) 6 (40.0)
Not conﬁrmed as TEE (SAB) 2 (12.5) 1 (6.7)
Type of event (by SOC), No. (%)
Cardiac disorders
MI 1 (6.2) 1 (6.7)
Acute MI 0 3 (20.0)
Myocardial ischemia 0 2 (13.3)
Nervous system disorders
Ischemic stroke 4 (25.0) 0
CVA 1 (6.2) 2 (13.3)
Embolic cerebral infarction 0 1 (6.7)
TIA 0 1 (6.7)
Acute CVA 0 1 (6.7)
Vascular disorders
Thrombosis in device 1 (6.2) 1 (6.7)
Venous thrombosis limb 3 (18.8) 0
Thrombosis 1 (6.2) 0
DVT 3 (18.8) 1 (6.7)
Thrombophlebitis 0 1 (6.7)
PE 0 1 (6.7)
Other 2 (12.5) 0
Severity of event by maximum intensity,
No. (%)
Mild 2 (12.5) 5 (33.3)
Moderate 7 (43.8) 6 (40.0)
Severe 7 (43.8) 4 (26.7)
Timing of event
Median, days 10 2
Mean, days 14 9
>1 wk postinfusion, No. (%) 4 (25.0) 11 (73.3)
SOC, System organ class.
Thromboembolic Events After Vitamin K Antagonist Reversal Milling et al24 hours (data not shown). There was also no indication of
an association between factor levels and events in the
plasma group (data not shown).
Levels of proteins C and S were also markedly
increased after 4F-PCC infusion.14,15 We observed no
signiﬁcant differences in median proteins C and S levels
between patients with and without thromboembolic
events at 0.5 hours (Figure E1, available online at
http://www.annemergmed.com) or 24 hours (data not
shown) after start of 4F-PCC infusion. Results were
similar for patients who received plasma (data not
shown).
We performed additional analyses to determine whether
factor levels above the upper limit of normal were
associated with events. In total, 43 of 191 patients (22.5%)
in the 4F-PCC group had at least 1 factor above the upper102 Annals of Emergency Medicinelimit of normal at 0.5 hours or 24 hours postinfusion
(Figure E2, available online at http://www.annemergmed.
com). However, only 3 of these 43 patients with factor
levels above the upper limit of normal experienced events
(patients K6 and K14 in the acute bleeding study and
patient K5 in the surgery study) (Figure E2, available
online at http://www.annemergmed.com).
LIMITATIONS
We did not power the randomized controlled trials
analyzed in this study to detect differences in safety outcomes
such as thromboembolic events. In addition, we could not
blind study staff and patients to treatment allocation because
plasma and prothrombin complex concentrate have distinctly
different appearances and administration procedures.
However, a blinded safety adjudication board reviewed serious
adverse events of interest, including thromboembolic events,
increasing the robustness of this data set. The board evaluated
only thromboembolic events deemed serious by unblinded
investigators,meaning events investigators deemednonserious
did not receive independent blinded review; however, the data
and safety monitoring board reviewed all events, serious and
nonserious, whether deemed related or not by investigators.
In addition, preoperative surgical patients may in some
ways be pathophysiologically distinct from hemorrhaging
patients; however, we provided patient-level data on all events,
allowing readers to draw their own conclusions. Finally, we
did not perform Doppler screening during or after the
study period, so it is possible that subclinical asymptomatic
thromboembolic disease was missed.
DISCUSSION
Reversal of anticoagulant therapy with prothrombin
complex concentrates may be associated with thromboembolic
events.13 Reversing vitamin K antagonist anticoagulation with
factor replacement by prothrombin complex concentrate or
plasma, or even by vitaminK1 alone or bymerely withdrawing
vitamin K antagonist therapy, exposes patients to the
underlying thromboembolic risk for which the vitamin K
antagonist was initially prescribed. Our studies afford
an opportunity to address some of the difﬁculties in
characterizing thromboembolic event risk because they
represent, to our knowledge, the largest controlled
assessments of a 4F-PCC and plasma, in which patients
were prospectively and rigorously followed for 45 days
postinfusion (for serious adverse events). Post hoc analysis
of combined safety data from these studies permitted a
detailed examination of the effect of anticoagulation
reversal strategies on thromboembolic events, allowing the
characterization of type of event, timing, and clinical
outcome to a degree of detail not previously reported.Volume 67, no. 1 : January 2016
Table 4. Comparison of characteristics between patients with thromboembolic events and the pooled study population.
Variables
Integrated Analysis
Patients With Events
(n[28)
Patients Without Events
(n[360)
Pooled Safety Population
(N[388)
Age, y
Mean (SD) [range], y 73.6 (12.2) [50–92] 69 (13) [26–96] 69.3 (13.4) [26–96]
70, No. (%) 18 (64.3) 196 (54.4) 214 (55.2)
Type of bleeding, No. (%)*
Gastrointestinal/other nonvisible 9 (32.1) 118 (32.8) 127 (32.7)
Visible 1 (3.6) 42 (11.7) 43 (11.1)
Intracranial hemorrhage 3 (10.7) 21 (5.8) 24 (6.2)
Musculoskeletal 2 (7.1) 16 (4.4) 18 (4.6)
Type of surgery/procedure, No. (%)†
Cranial neurosurgical 1 (3.6) 1 (0.3) 2 (0.5)
Cardiothoracic surgical 1 (3.6) 4 (1.1) 5 (1.3)
Major orthopedic surgical 5 (17.9) 33 (9.2) 38 (9.8)
Other surgical 2 (7.1) 97 (26.9) 99 (25.5)
Invasive 4 (14.3) 28 (7.8) 32 (8.2)
Reason for oral VKA therapy, No. (%)
Arrhythmia 19 (67.9) 175 (48.6) 194 (50.0)
Vascular disease 0 59 (16.4) 59 (15.2)
Artiﬁcial heart or joint 1 (3.6) 53 (14.7) 54 (13.9)
Remote thromboembolic event 8 (28.6) 63 (17.5) 71 (18.3)
Other 0 10 (2.8) 10 (2.6)
*For patients enrolled in the bleeding study (NCT00708435) only.
†For patients enrolled in the surgery study (NCT00803101) only.
Milling et al Thromboembolic Events After Vitamin K Antagonist ReversalThe percentage of patients with thromboembolic events
in each treatment groupwas similar (4F-PCC: 7.3%; plasma:
7.1%). Furthermore, the proportions of patients with
treatment-related events (investigator assessed), serious
events, and treatment-related serious events (assessed by the
blinded safety adjudication board) in each group were also
found to be similar. Although some of the cases were assessed
as possibly related to study treatment (4F-PCC or plasma),
most patients were not receiving anticoagulant therapy at the
event, and such failure to resume anticoagulation in patients
with existing thromboembolic risks can be considered a
major contributor to thromboembolism.16,17
We observed some potential differences between plasma
and 4F-PCCwith respect to the incidence of thromboembolic
events subtypes. There were 8 vascular events in the 4F-
PCC group (of which 4 were deep venous thromboses
and none were pulmonary embolisms) versus 4 in the
plasma group (including 1 deep venous thrombosis and 1
pulmonary embolism), but 1 cardiac event in the 4F-PCC
group versus 6 in the plasma group. If the 2 data and safety
monitoring board–referred, safety adjudication
board–adjudicated cases of myocardial ischemia in the
plasma group are removed from the analysis, the number of
cardiac events observed in the plasma group remains higher
than in the 4F-PCC group (4 versus 1). The increase in
cardiac events in the plasma group might be due to
increased blood volume after plasma transfusion, which
would overwhelm cardiac output and may lead to ischemia.Volume 67, no. 1 : January 2016Although this suggests that appropriate monitoring may be
required in plasma-treated patients with cardiac-related
comorbidities, these results should be interpreted with
caution owing to the small number of reported cases.
The increase in vitamin K-dependent factors as a
result of study treatment could potentially inﬂuence the
occurrence of thromboembolic events. However, in this
analysis, there did not appear to be any consistent
relationship between the timing of the events and the half-
lives of the administered factors. In addition, although the
incidence of events was similar in both groups, events in
the plasma group tended to cluster in the ﬁrst week after
study treatment, whereas events in the 4F-PCC group
clustered a week later. It is plausible that the cluster of
events that occurred on days 1 to 7 (11 and 5 in the plasma
and 4F-PCC groups, respectively) is more likely to be
related to the infused factors (and 10 of these 16 events
were deemed at least possibly so by the investigators or the
safety adjudication board) compared with events that
occurred after day 7. Indeed, by the second week, factor
levels would be more a reﬂection of the administered
vitamin K and endogenous coagulation factor synthesis
than of study product. Thus, it may be that the latter 15
events (11 and 4 in the 4F-PCC and plasma groups,
respectively), which occurred 8 or more days after infusion
(some even several weeks later), are more a consequence of
preexisting thrombotic conditions rather than the infusion
of study product per se. Nevertheless, unblindedAnnals of Emergency Medicine 103
Thromboembolic Events After Vitamin K Antagonist Reversal Milling et alinvestigators deemed 7 events that occurred after week 1
(all in the 4F-PCC group) at least possibly related to the
study treatment (Figure). Regardless of the cause of events,
the observations of this study suggest that patients with
high risk for thromboembolic events may beneﬁt from
resumption of vitamin K antagonist therapy as soon as the
clinical circumstances allow. In patients with intracranial
hemorrhage, the 2014 American Heart Association/
American Stroke Association guidelines suggest resumption
of anticoagulation at greater than or equal to 1 week.18
In terms of the potential relationship between vitamin
K–dependent factors and thromboembolic events, patients
who received a higher dose of study product were not more
likely to have an event in this analysis. Furthermore, the
lack of notable differences in median factor levels for
patients with or without events indicates that the levels of
the infused factors may not play a major role in
determining events.
In conclusion, these results indicate that the use of 4F-
PCC is not associated with an overall increased risk of
thromboembolic events compared with plasma in patients
requiring urgent anticoagulation reversal owing to major
hemorrhage or before urgent surgical procedures. Differences
in the number of thromboembolic event subtypes were
observed between treatment groups, although the small
number of events in each group limits data interpretation.
Considering the age-related comorbidities and risk factors for
thrombosis in this patient population, it is possible that events
occur with a similar frequency irrespective of the reversal agent
used.16,17
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Table E1. Dose of study treatment per baseline international
normalized ratio.
Baseline INR
Dose of 4F-PCC,
IU of FIX/kg Body Weight*
Plasma, mL/kg
Body Weight*
2–<4 25 10
4–6 35 12
>6 50 15
FIX, Factor IX.
*The dose calculation was based on 100-kg body weight for patients weighing greater
than 100 kg. 4F-PCC was administered at an infusion rate of less than or equal to 3
IU/kg per minute. The plasma infusion rate was at the discretion of the clinical team
in both the acute bleeding and surgery studies; however, in the acute bleeding study,
an infusion rate of 1 unit per 0.5-hour interval was recommended by the protocol.
Thromboembolic Events After Vitamin K Antagonist Reversal Milling et alTable E2. Causality by event type.
Types of Disorders
4F-PCC Plasma
Total Number of Events Causality* Total Number of Events Causality*
AEs SAEs Investigator SAB AEs SAEs Investigator SAB
Cardiac disorders 0 1 0 0 1 5 3 4
Nervous system disorders 1 4 2 2 2 3 1 1
Vascular disorders 4 4 6 3 2 2 1 1
*Causality indicates events at least possibly related to treatment in the opinion of the investigator/SAB. The investigator reviewed AEs and SAEs. The SAB only reviewed SAEs.
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Table E3. Additional information on thromboembolic events.
Patient Study
Onset
Day* Indication for VKA
Event Consistent
With Indication
for VKA†
Actual
Dose, IU/kg
Receiving
Anticoagulant
at Event Additional Risk Factors‡
4F-PCC
K1 Bleeding 1 Portal vein
thrombosis
Yes 50.0 No CAD, DM, HTN, end-stage renal
disease, obesity
K2 Bleeding 1 DVT Yes 35.0 No AF, CHF, DM, HTN, CAD
K3 Surgery 1 Mitral valve replacement
and AF
Yes 50.0 (overdose,
should have
been 25.0)
No Cardiomyopathy, CHF, HTN, medication
error, DVT left arm, atrial ﬂutter
K4 Surgery 6 DVT No 25.0 Yes Metastatic prostate cancer
K5 Surgery 7 AF No 25.0 No End-stage renal disease, hemodialysis,
HTN, CAD, stroke
K6 Bleeding 9 DVT Yes 50.0 No HTN
K7 Bleeding 9 AF/St Jude’s valve Yes 35.0 No Blood transfusions, CAD, CVA, HTN, MI
K8 Bleeding 10 AF Yes 25.0 Yes Blood transfusions, CHF, DVT/PE,
thrombocytosis
K9 Surgery 10 AF Yes 25.0 Yes CAD, CHF, HTN, DM, atrial ﬂutter,
chronic renal insufﬁciency, chronic
kidney disease stage 3
K9 Surgery 11 As above No As above As above As above
K10 Surgery 12 DVT Yes 50.0 No PE
K11 Bleeding 13 AF No 25.0 No CAD, HTN, immobility (multiple
fractures), head trauma, MI
K11 Bleeding 29 As above No As above No As above
K12 Surgery 19 AF No 25.0 No Atrial ﬂutter, PAF with RVR, sick sinus
syndrome, HTN, right breast ductal
carcinoma
K13 Bleeding 38 AF No 25.0 No Cardiomyopathy, CVA, DM, HTN
K14 Bleeding 43 AF Yes 35.0 No CAD, CHF, HTN, TIA
Plasma
P1 Bleeding 1 AF No 4.4 No CAD, CHF and cardiomyopathy, EF of
27%, HTN, MI
P1 Bleeding 4 As above No As above No As above
P2 Bleeding 1 AF No 6.0 No CAD, CHF, cardiomyopathy, EF of 68%,
CVA DM, HTN, ischemic colitis , SMA-
occlusion hx
P3 Bleeding 1 Aortic valve replacement No 13.5 No CAD, CHF, DM, HTN, MI
P4 Bleeding 1 AF Yes 17.7 No HTN, DM
P5 Bleeding 1 AF Yes 6.5 Yes HTN, CAD, CHF, mitral valve
incompetence, MI
P6 Surgery 1 DVT No 12 No Hypercoagulable state of unknown
cause
P7 Surgery 1 DVT Yes 7 No HTN, PE, obesity
P8 Surgery 2 AF Yes 11 No CHF, HTN
P9 Surgery 4 AF No 10 No Severe AS, DM, obesity, EF 25%,
hypotension
P10 Surgery 6 AF Yes 12 Yes CHF
P11 Bleeding 13 AF No 9.9 Yes CAD, stent placement
P12 Surgery 16 AF No 10 No CHF, immobility
P13 Bleeding 22 AF Yes 10.0 Yes DM, ARF and CRF, CHF, HTN, obesity
P14 Surgery 56§ DVT No 10 No Intermittent irregular heart rhythm,
HTN, CAD, DM
CAD, Coronary artery disease; DM, diabetes mellitus; HTN, hypertension; CHF, congestive heart failure; PAF, paroxysmal atrial ﬁbrillation; RVR, rapid ventricular response; EF,
ejection fraction; SMA, superior mesenteric artery; hx, history; AS, aortic stenosis; ARF, acute renal failure; CRF, chronic renal failure.
The vena cava ﬁlter insertion (K4) was not considered a thromboembolic event by the lead author. The Food and Drug Administration assessed some of the AEs and
thromboembolic events differently from the study investigators/SAB, resulting in a difference in the numbers of thromboembolic events reported in the package insert for the 4F-
PCC in the United States (Kcentra)19 compared with published study results.14,15
*Onset study day of thromboembolic event, day of study product infusion is day 1.
†Thromboembolic event considered consistent with the patient’s original VKA indication by the lead author.
‡In addition to indication for VKA treatment.
§Acute CVA was diagnosed on day 56 but included in the thromboembolic event analysis because of uncertain timing related to the start of the event.
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Figure E1. Median levels of coagulation factors and proteins C and S 0.5 hours after start of 4F-PCC infusion (integrated analysis).
F, Factor. þ Represents the mean of the data. The line in the middle of the box represents the median. The upper and lower
bounds of the box are the 75th and 25th percentiles, respectively. The top of the whisker is the maximum (or 75th percentileþ
[1.5interquartile range] where outliers are present). The bottom of the whisker is the minimum (or 25th percentile
[1.5interquartile range] where outliers are present).
Thromboembolic Events After Vitamin K Antagonist Reversal Milling et al
105.e3 Annals of Emergency Medicine Volume 67, no. 1 : January 2016
Figure E2. 4F-PCC–treated patients with levels of at least 1 of the 4 vitamin K–dependent factors above the upper limit of normal
in the acute bleeding and surgery studies. Normal adult reference range (95% range)20: FII¼70% to 146%, FVII¼67% to 143%,
FIX¼55% to 163%, FX¼70% to 152%. *Patient had elevated FVII levels at 30 minutes and 24 hours postinfusion. ULN, Upper limit
of normal.
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Investigators identiﬁed AEs as possible
thromboembolic events, using the following predeﬁned
standardized terms: “embolic and thromboembolic events,
arterial” (eg, [acute] MI, ischemic stroke, and TIA);
“embolic and thromboembolic events, venous” (eg, DVT,
PE, thrombophlebitis, vena cava ﬁlter insertion, and
venous thrombosis limb); and “embolic and
thromboembolic events, vessel type unspeciﬁed and
mixed arterial and venous” (eg, catheter-related105.e5 Annals of Emergency Medicinecomplication, CVA, embolic cerebral infarction,
thrombosis, and thrombosis in device).
The blinded SAB reviewed all serious thromboembolic
events identiﬁed by the investigators on a case-by-case basis.
The unblinded independent data and safety monitoring
board could also refer cases to the SAB not coded as
thromboembolic events but suspected as such. The study
protocol dictated that in cases of disagreement between the
unblinded investigator assessment and the blinded SAB
assessment, the SAB determination would stand as ﬁnal.Volume 67, no. 1 : January 2016
